Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France

• المؤلفون الرئيسيون: Matthieu Lehmann (مؤلف), Elisangela Arbo (مؤلف), Jean-Luc Pouly (مؤلف), Paul Barrière (مؤلف), Lauren Amy Boland (مؤلف), Samuel George Bean (مؤلف), Julian Jenkins (مؤلف)
• التنسيق: كتاب
• منشور في: Elsevier, 2024-06-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Objective: The study assessed cost-effectiveness of follitropin alfa biosimilar versus the originator in terms of cost per cumulative live-birth (CLB) for the French healthcare system based on real-world evidence. Follitropin alfa biosimilars have been shown to have comparable clinical outcomes to t...